Alkem Laboratories reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for Q1 FY26 to Rs. 664.3 crore, up from Rs. 545.2 crore in the same period last year. 

Revenue from operations increased 11.2 per cent Y-o-Y to Rs. 3,371 crore in Q1 FY26 from Rs. 3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets.

According to IQVIA (SSA) data, Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent, with overall volume growth of 2.9 per cent, outperforming the market by 140 basis points. India sales contributed 68.3 per cent to total sales, with notable growth in gastrointestinal, VMN, pain, anti-diabetics, neuro/CNS, respiratory, and derma therapies.

Commenting on the results, Dr. Vikas Gupta, CEO of Alkem, said, “Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.”

Alkem is the fifth-largest pharmaceutical company in India. It operates 18 manufacturing facilities and advanced R&D centres, supplying generic formulations, APIs, and biosimilars to India, the US, Latin America, Australia, and other Asian markets.